Lee Danner & Bass Inc. Invests $41,000 in Gilead Sciences, Inc. (NASDAQ:GILD)

Lee Danner & Bass Inc. bought a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) during the 4th quarter, Holdings Channel.com reports. The firm bought 440 shares of the biopharmaceutical company’s stock, valued at approximately $41,000.

Other institutional investors have also added to or reduced their stakes in the company. HHM Wealth Advisors LLC boosted its holdings in Gilead Sciences by 118.5% in the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 154 shares during the last quarter. YANKCOM Partnership bought a new stake in Gilead Sciences in the fourth quarter valued at approximately $28,000. Decker Retirement Planning Inc. bought a new stake in Gilead Sciences in the fourth quarter valued at approximately $29,000. Crews Bank & Trust bought a new stake in Gilead Sciences in the fourth quarter valued at approximately $31,000. Finally, Stephens Consulting LLC boosted its holdings in Gilead Sciences by 325.0% in the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 260 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.

Insider Transactions at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 17,929 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $118.17, for a total transaction of $2,118,669.93. Following the completion of the transaction, the chief financial officer now owns 169,061 shares in the company, valued at approximately $19,977,938.37. This represents a 9.59 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last 90 days, insiders sold 302,785 shares of company stock worth $30,503,250. 0.29% of the stock is owned by company insiders.

Gilead Sciences Stock Up 1.1 %

Shares of NASDAQ:GILD opened at $107.08 on Friday. The company has a market capitalization of $133.35 billion, a PE ratio of 289.41, a price-to-earnings-growth ratio of 0.71 and a beta of 0.21. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The business has a fifty day moving average price of $103.68 and a two-hundred day moving average price of $93.85. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $119.96.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Friday, March 14th will be paid a dividend of $0.79 per share. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date is Friday, March 14th. This represents a $3.16 annualized dividend and a dividend yield of 2.95%. Gilead Sciences’s dividend payout ratio is presently 854.05%.

Analyst Upgrades and Downgrades

GILD has been the topic of several analyst reports. Deutsche Bank Aktiengesellschaft upgraded Gilead Sciences from a “hold” rating to a “buy” rating and upped their target price for the company from $80.00 to $120.00 in a report on Tuesday, February 18th. Morgan Stanley boosted their price target on Gilead Sciences from $123.00 to $130.00 and gave the company an “overweight” rating in a research note on Tuesday, March 11th. DZ Bank raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 price target on the stock in a research note on Thursday, February 13th. BMO Capital Markets boosted their price target on Gilead Sciences from $110.00 to $115.00 and gave the company an “outperform” rating in a research note on Wednesday, February 12th. Finally, Bank of America boosted their price target on Gilead Sciences from $116.00 to $126.00 and gave the company a “buy” rating in a research note on Wednesday, March 5th. Eleven research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $104.52.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.